IIPR Q1 Leasing Picks Up, but Dividend and Refi Risks Persist

What happened

IIPR reported Q1 2026 results highlighting nearly 400,000 square feet of executed leases, signaling demand for its cannabis facilities. The company also claimed deliberate steps to strengthen its balance sheet, though no specifics were provided. However, the master report warns that tenant defaults and a dividend payout exceeding AFFO persist, with AFFO per share dropping to $1.71 in Q3 2025 against a $1.90 quarterly dividend. The IQHQ life-science investment diversifies but adds concentration risk and leverages the balance sheet further. With the $300 million notes maturing in May 2026, the company faces a refinancing test that could force a dividend cut or dilutive equity raise.

Implication

The Q1 leasing uptick provides a modest positive but does not alter the fundamental cash flow deficiency. The dividend remains above run-rate AFFO, and management's flexibility to borrow or issue equity to pay it signals fragility. The IQHQ investment diversifies but is a concentrated credit bet that will take time to contribute. The key catalyst remains the May 2026 debt refinancing, which could increase leverage or dilute shareholders. Given the risk of a dividend reset, the stock's high yield should be viewed as a warning, not an opportunity.

Thesis delta

The Q1 leasing data offers a modest improvement but does not change the thesis that IIPR's dividend is unsustainable and cash flows declining. The core risks—tenant defaults and the 2026 debt refinancing—remain unchanged. The incremental leasing does not offset the structural gap between AFFO and the dividend, and the high yield remains a distress signal.